RECQL4 depletion led to increased sensitivity of the ovarian cancer cells to cisplatin and olaparib, a PARP inhibitor, which suggests that RECQL4 may be a critical component in the resistance of ovarian malignant cells to cisplatin. This evidence concerns the gene RECQL4 and ovarian cancer.